ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Biogen to develop zinc finger therapies with Sangamo

by Ryan Cross
March 7, 2020 | APPEARED IN VOLUME 98, ISSUE 9

 

Biogen is paying Sangamo Therapeutics $350 million up front to develop gene therapies for neurological diseases. The deal focuses on Sangamo’s zinc finger protein transcription factors (ZFP-TFs), which dial the expression of genes up or down. The two most advanced programs in the collaboration use ZFP-TFs to decrease levels of tau proteins and α-synuclein proteins, implicated in Alzheimer’s and Parkinson’s disease, respectively. Biogen has exclusive rights to develop Sangamo’s ZFP-TFs for up to 10 additional targets.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment